Top Abstract Purchase Related
Home
>
Node
>
Subnode

Coadministration of HMG-CoA reductase inhibitors, atorvastatin and rosuvastatin, does not affect contraceptive efficacy of centchroman

Sharma, A.; Jaiswal, S.; Shukla, M.; Ravindrachary, K.; Lal, J.

European Journal of Contraception and Reproductive Health Care the Official Journal of the European Society of Contraception 20(3): 231-235

2015

ISSN/ISBN: 1473-0782
PMID: 25798535
DOI: 10.3109/13625187.2015.1017756
Document Number: 627122
The study aimed to investigate the effect of concomitant use of atorvastatin or rosuvastatin on the pharmacokinetic and pharmacodynamic profile of centchroman, a non-steroidal female oral contraceptive. A rat model was used to predict pharmacokinetic drug-drug interactions between centchroman and atorvastatin or rosuvastatin. A dried blood spot sampling technique followed by liquid chromatography-tandem mass spectrometry detection was employed for analysis of the pharmacokinetic interaction study samples. Sperm-positive female rats were investigated for postcoital contraceptive activity of centchroman with or without coadministration of atorvastatin or rosuvastatin. Coadministration of atorvastatin or rosuvastatin may increase the systemic availability of centchroman in blood, but it does not affect the pharmacodynamic profile of centchroman. Atorvastatin or rosuvastatin may be prescribed with centchroman without compromising the contraceptive efficacy of centchroman.

Document emailed within 0-6 h
Secure & encrypted payments

Liping, Z.; Xiufang, L.; Tao, Y.; Baomin, Z.; Houshuai, T. 2018: Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis Pakistan Journal of Pharmaceutical Sciences 31(5(Special): 2203-2208
2015: Switching from high-efficacy lipid-lowering therapies [atorvastatin or rosuvastatin] to simvastatin and the results on low-density lipoprotein cholesterol level Journal of the Medical Association of Thailand 98(1): 21-25
Hydzik, P.; Szpak, D. 2011: Side effects of the HMG-CoA reductase inhibitors (statins). Lupus erythematosus induced by Atorvastatin therapy Przeglad Lekarski 68(8): 495-498
Gogolashvili, N.G. 2012: Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine Kardiologiia 52(7): 84-92
Bousquet, P.; Gayet, J-Louis. 2003: Pharmacologic characteristics of rosuvastatin, a new HMG-CoA reductase inhibitor Therapie 58(2): 113-121
McKenney, J.; Ballantyne, C.M.; Feldman, T.A.; Brady, W.E.; Shah, A.; Davies, M.J.; Palmisano, J.; Mitchel, Y.B. 2005: LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD Medgenmed: Medscape General Medicine 7(3): 3
Ott, C.; Ritt, M.; Titze, S.I.; Schäufele, T.; Schmieder, R.E. 2009: Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia Journal of Nephrology 22(5): 675-681
Nakajima, S.T.; Pappadakis, J.; Archer, D.F. 2016: Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptive Contraception 93(1): 52-57
Anand, N.; Ray, S. 1977: Centchroman--a post-coital contraceptive agent Indian Journal of Experimental Biology 15(12): 1142
Gupta, R.C.; Paliwal, J.K.; Nityanand, S.; Asthana, O.P.; Lal, J. 1995: Centchroman: a new non-steroidal oral contraceptive in human milk Contraception 52(5): 301-305
Srivastava, R.; Puri, V.; Srimal, R.C.; Dhawan, B.N. 1986: Prostanoid mediated effects of centchroman, a non-steroidal oral contraceptive Agents and Actions 18(5-6): 596-599
Schweiger, C. 2003: Clinical trials with rosuvastatin: efficacy and safety of its use Italian Heart Journal: Official Journal of the Italian Federation of Cardiology 4(Suppl 7): 33s-46s
Ivleva, A.I. 2005: Efficacy of lipid correcting therapy with the use of rosuvastatin Kardiologiia 45(6): 71-80
Ullah, F.; Afridi, A.K.; Rahim, F.; ur Rahman, S.; Ashfaq, M. 2015: Efficacy of 5 Mg and 10 Mg Rosuvastatin in Type-2 Diabetes Mellitus with Hypercholesteroalemia Journal of Ayub Medical College Abbottabad: Jamc 27(3): 564-568
Bifano, M.; Sevinsky, H.; Hwang, C.; Kandoussi, H.; Jiang, H.; Grasela, D.; Bertz, R. 2014: Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate Antiviral Therapy 19(5): 511-519
Shenoy, B.D.; Udupa, N.; Kamath, R.; Devi, P.U. 1999: Evaluation of anti-tumor efficacy of injectable Centchroman in mice bearing Ehrlich ascites carcinoma Indian Journal of Physiology and Pharmacology 43(2): 259-262
Drapkina, O.M.; Eliashevich, S.O. 2015: Efficacy and Safety of Rosuvastatin in Patients of Different Risk Groups of Developing Cardiovascular Kardiologiia 55(2): 72-81
Piamsomboon, C.; Laothavorn, P.; Saguanwong, S.; Chatlaong, B.; Nasawadi, C.; Tanprasert, P.; Pongsiri, K. 2002: Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia Journal of the Medical Association of Thailand 85(3): 297-300
Cawello, W.; Rosenkranz, B.; Schmid, B.; Wierich, W. 2013: Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers Epilepsia 54(3): 530-536
Pola, P.; Kumar, R.; Reddy, A.P.; Rajagopal, G.; Harinarayan, C.V.; Suresh, V.; Suchitra, M.M.; Sachan, A. 2009: Efficacy of low dose atorvastatin in diabetic dyslipidaemia Journal of the Indian Medical Association 107(11): 807-809